Clinical effects of wasabi extract containing 6-MSITC on myalgic encephalomyelitis/chronic fatigue syndrome: an open-label trial

BioPsychoSocial Medicine

Research

Yu Yamada¹  Takakazu Oka²  Battuvshin Lkhagvasuren³  Mutsuhiro Nakao³  Ryuji Hiramatsu⁴  Yo-ichi Nabeshima⁴  Ryota Nakajima⁵  Masanobu Kanou⁵ 

[1] Department of Psychosomatic Medicine, International University of Health and Welfare Hospital, Iguchi 537-3, 329-2763, Nasushiobara-Shi, Tochigi-Ken, Japan;Department of Psychosomatic Medicine, International University of Health and Welfare Hospital, Iguchi 537-3, 329-2763, Nasushiobara-Shi, Tochigi-Ken, Japan;Department of Psychosomatic Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, 286-8520, Narita, Chiba, Japan;Department of Psychosomatic Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, 286-8520, Narita, Chiba, Japan;PAL LIMITED, 10-31-105, Furuedai 3-Chome, Suita-Shi, 565-0874, Osaka, Japan;TEIJIN LIMITED, 2-1, Kasumigaseki 3-Chome, Chiyoda-Ku, 100-8585, Tokyo, Japan;

关键词: Myalgic encephalomyelitis/chronic fatigue syndrome;    6-MSITC;    Brain fog;    Cognitive impairment;    Fatigue;    Performance status;    Clinical effect;   

DOI  :  10.1186/s13030-022-00255-0

 received in 2022-09-22, accepted in 2022-11-23,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundWasabi (Eutrema japonicum) is a common pungent spice used in Japan. 6-Methylsulfinylhexyl isothiocyanate (6-MSITC) found in the rhizome of wasabi has been shown to have anti-inflammatory and antioxidant effects, as well as improve neuroinflammation and memory. Therefore, we hypothesized that these effects would be beneficial for treating myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The present study was conducted to investigate the effectiveness of wasabi extract containing 6-MSITC on ME/CFS in an open-label trial.MethodsFifteen patients (3 males, 12 females, 20–58 years old) were orally administered wasabi extract (9.6 mg of 6-MSITC/day) for 12 weeks. The following parameters and test results were compared pre- and post-treatment: performance status (PS), self-rating questionnaires, pressure pain threshold (PPT) on the occiput, Trail Making test-A (TMT-A), and hemodynamic patterns determined by an active standing test.ResultsAfter treatment with 6-MSITC, PS improved significantly (p = 0.001). Although the scores on the 11-item Chalder Fatigue scale (CFS-11) and numerical rating scale (NRS) of fatigue did not show significant changes, subjective symptoms improved significantly, including headache frequency (4.1 to 3.0 times/week, p = 0.001) and myalgia (4.1 to 2.4 times/week, p = 0.019), NRS brain fog scores (5.7 to 4.5, p = 0.011), difficulty finding appropriate words (4.8 to 3.7, p = 0.015), photophobia (4.8 to 3.5, p = 0.008), and the Profile of Mood Status vigor score (46.9 to 50.0, p = 0.045). The PPT of the right occiput (17.3 to 21.3 kPa, p = 0.01) and TMT-A scores (53.0 to 38.1 s, p = 0.007) also changed, suggesting reduced pain sensitivity, and improved cognitive function, respectively. Orthostatic patterns determined by a standing test did not show remarkable changes. There were no serious adverse reactions.ConclusionThis study suggests that 6-MSITC improves PS as well as subjective symptoms such as pain and cognitive dysfunction, and psychological vitality of patients with ME/CFS. It also improved cognitive performance and increased pain thresholds in these patients. 6-MSITC may be a promising therapeutic option especially for improving cognitive dysfunction associated with ME/CFS.

【 授权许可】

CC BY   
© The Author(s) 2022